2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135741
    NYX-2925 2012536-16-0 98.98%
    NYX-2925 is an orally active NMDAR modulator. NYX-2925 restores levels of activated Src and Src phosphorylation sites on GluN2A and GluN2B in the mPFC. NYX-2925 shows no effect on CAMKII, and any addictive or sedative/ataxic side effects. NYX-2925 can be used for research of a variety of NMDA receptor-mediated central nervous system disorders.
    NYX-2925
  • HY-142647
    EB-42486 2390475-81-5 99.62%
    EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50: < 0.2 nM). EB-42486 can be used in the research of Parkinson's disease.
    EB-42486
  • HY-147294
    Nivasorexant 1435480-40-2 99.74%
    Nivasorexant (ACT-539313) is an orally active, blood-brain barrier penetrant, selective orexin OX1R inhibitor. Nivasorexant specifically blocks central OX1Rs without affecting OX2Rs, and exhibits competitive inhibitory activity against CYP2C8, CYP2C9, CYP2C19 and CYP3A4 (IC50 values are 25 μM, 8.6 μM, 1.6 μM, 19 μM/44 μM, respectively). Nivasorexant significantly reduces binge-like eating behavior of highly palatable food in rat models and has long-acting properties. Nivasorexant shows no relevant off-target activity against over 130 selected proteins, exhibits favorable safety profiles, and can be used for studies related to binge eating disorder.
    Nivasorexant
  • HY-148629
    GDC-0134 1637394-01-4 99.18%
    GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases.
    GDC-0134
  • HY-152843
    Fazamorexant 1808918-69-5 98.95%
    Fazamorexant (YZJ-1139) is an orally active dual orexin receptor antagonist, with an IC50 of 32 nM against OX1R and an IC50 of 41 nM against OX2R. Fazamorexant prolongs total sleep time and improves sleep efficiency. Fazamorexant is applicable to related research on insomnia.
    Fazamorexant
  • HY-P10019
    Pegsebrenatide 2243292-26-2
    Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension. Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis. Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis.
    Pegsebrenatide
  • HY-P99200
    Fulranumab 902141-80-4
    Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain.
    Fulranumab
  • HY-P990011
    Sabirnetug 2747959-38-0
    Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.
    Sabirnetug
  • HY-22385
    Salsolidine 5784-74-7
    Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor.
    Salsolidine
  • HY-N0573S
    Umbelliferone-d5 1215373-23-1 ≥98.0%
    Umbelliferone-d5 (7-Hydroxycoumarin-d5) is the deuterium labeled Umbelliferone (HY-N0573 ). Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats.
    Umbelliferone-d5
  • HY-10174
    PD184161 212631-67-9 98.08%
    PD184161 is an orally active MEK inhibitor. PD184161 inhibits MEK activity (IC50=10-100 nM) in a time- and concentration-dependent manner. PD184161 inhibits cell proliferation and induces apoptosis. PD184161 produces depressive-like behavior.
    PD184161
  • HY-10457
    Velusetrag 866933-46-2 99.49%
    Velusetrag (TD-5108) is an orally active, potent and selective agonist of serotonin 5-HT4 receptor (5-HT4R), with a pKi of 7.7. Velusetrag exhibits no affinity (Ki>10 μM) for 5-HT2A and 5-HT2B receptors. Velusetrag can be used for the research of gastrointestinal diseases and Parkinson's disease.
    Velusetrag
  • HY-12158
    VU0238441 85511-68-8 99.87%
    VU0238441 is a pan muscarinic acetylcholine receptor (mAChR) positive allosteric modulator (PAM) with EC50s of 3.2 μM, 2.8 μM, 2.2 μM, 2.1 μM, >10 μM for M1, M2, M3, M5 and M4, respectively.
    VU0238441
  • HY-12324
    SB269652 215802-15-6 98.13%
    SB269652 is the first drug-like allosteric modulator of the dopamine D2 receptor (D2R); a new chemical probe that can differentiate D2R monomers from dimers or oligomers depending on the observed pharmacology.
    SB269652
  • HY-12390
    Lofepramine 23047-25-8 99.36%
    Lofepramine (Lopramine) is a modified tricyclic and orally active antidepressant. Lofepramine inhibits the uptake of Noradrenaline (NA) (HY-13715) and 5-hydroxytryptamine (5-HT) with IC50s of 2.7 μM and 11 μM, respectively. Lofepramine exerts its antidepressant activity by promoting noradrenergic neurotransmission. Lofepramine also enhances serotonergic neurotransmission by inhibiting neuronal uptake of 5-HT and tryptophan pyrrolase. Lofepramine exhibits significant anxiolytic properties. .
    Lofepramine
  • HY-12436
    NTRC-824 1623002-61-8 98.2%
    NTRC-824 (Compound 5) is a potent, selective and neurotensin-like nonpeptide neurotensin receptor type 2 (NTS2) antagonist with an IC50 of 38 nM and a Ki of 202 nM. NTRC-824 is >150-fold selectivity for NTS2 over NTS1 (Ki >30 μM).
    NTRC-824
  • HY-12439
    ML380 1627138-52-6 99.87%
    ML380 is a potent, subtype-selective, and brain-penetrant positive allosteric modulator (PAM) of M5 mAChR, with EC50s of 190 and 610 nM for human and rat M5, respectively. ML380 exhibits moderate selectivity versus the M1 and M3 mAChR subtypes. ML380 could increase the affinity of ACh for the M5 mAChR.
    ML380
  • HY-12499
    (S)-Willardiine 21416-43-3 ≥98.0%
    (S)-Willardiine ((-)-Willardiine) is a subtype-selective glutamate receptor agonist and the active isomer of Willardiine. Willardiine binds to and activates hGluR1, hGluR2, hGluR4 and hGluR5, with Ki values of 3.6 nM and 0.24 nM for hGluR4 and hGluR5, respectively. (S)-Willardiine is used to investigate the distribution and physiological functions of glutamate receptor subunits in the central nervous system.
    (S)-Willardiine
  • HY-12502
    Efonidipine 111011-63-3 99.88%
    Efonidipine (NZ-105) is an orally active dual L-type and T-type calcium channel blocker (CCB) with IC50 values of 1.8 and 350 nM, respectively. Efonidipine inhibits SARS-CoV-2 main protease. Efonidipine modulates adrenal steroidogenesis by increasing the expression of steroidogenic acute regulatory protein (StAR), dbcAMP-or angiotensin II-induced StAR mRNA expression and DHEA-S production, while suppressing the biosynthesis of aldosterone and cortisol. Efonidipine reduces plasma aldosterone levels in vivo. Efonidipine improves cardiac function in heart failure models by inhibiting T-type calcium channels (via both tonic and use-dependent blockade), independently of blood pressure reduction. Efonidipine can be used for research in hypertension, heart failure, and disorders involving dysregulated steroid hormone synthesis.
    Efonidipine
  • HY-13059
    SDZ 220-581 174575-17-8 98.76%
    SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7.
    SDZ 220-581
Cat. No. Product Name / Synonyms Application Reactivity